A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults

NCT04871113 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: GSK3810109A
BIOLOGICAL: Dolutegravir+lamivudine SOC regimen

Sponsor

ViiV Healthcare